Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Annelize, Koch"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract OCS-05 (aka BN201) is a peptidomimetic that binds to serum glucocorticoid kinase-2 (SGK2), displaying neuroprotective activity. The objective of this randomized, double-blind 2-part study was to test safety and pharmacokinetics of OCS-05 adm
Externí odkaz:
https://doaj.org/article/6d807dfed4874d34b9a365717f80f1db
Autor:
Shahzadgai Khan, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation, and future challenges facing early phase drug development as we move into the second decade of the 21th century. The
Externí odkaz:
https://doaj.org/article/126a543321ad49788d3af82a37356081
Autor:
Susan Reijntjes, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Peter Scholes, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on the changing face of early phase drug development and opened with a keynote speech concerning the revolution in pharmaceutical medicine over the l
Externí odkaz:
https://doaj.org/article/142ed6f8be4d431691147e0fb3990447
Publikováno v:
Blood. 140:460-461
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca37d25d1d59b1297663218d9e9d21e3
https://doi.org/10.1182/blood-2022-159631
https://doi.org/10.1182/blood-2022-159631
Autor:
Stefan Roepcke, Grace Chen, Eric R. Fedyk, Annelize Koch, Glennda Smithson, Lin Zhao, Jose Estevam, Lachy McLean, Jianchang Lin, Gezim Lahu
Publikováno v:
British Journal of Clinical Pharmacology
Aims This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 antibody TAK-079. Methods A randomised, double-blind, placebo-controlled trial of a single intravenous (i.v.) infusion or subcutaneous (s.c.) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c02cd90eaceea3dd1c3666267ebd5f
https://doi.org/10.1111/bcp.14241
https://doi.org/10.1111/bcp.14241
Publikováno v:
The Journal of Clinical Pharmacology. 60:931-941
ACT-539313 is a potent and selective orexin-1 receptor antagonist. CYP3A is the major cytochrome P450 (CYP) enzyme involved in the metabolism and clearance of ACT-539313 in man. The main objective of this study was to investigate the effect of ACT-53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a45b1401d368d57cd1f5de0f8b1f73
https://doi.org/10.1002/jcph.1588
https://doi.org/10.1002/jcph.1588
Autor:
Martin Coenen, Craig B. Langman, Bernd Hoppe, Michelle A. Baum, Kelly Barrios, David McDougall, Annelize Koch, Sander F. Garrelfs, Aniruddha Amrite, Jaap W. Groothoff, Graham Lipkin, Gesa Schalk, Pierre Cochat
Publikováno v:
Kidney international. Nature Publishing Group
Primary hyperoxaluria (PH) is a family of ultra-rare autosomal recessive inherited disorders of hepatic glyoxylate metabolism characterized by oxalate overproduction. Nedosiran is an RNA interference agent that inhibits hepatic lactate dehydrogenase,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f77e773f290169ac0ad9c5fbd8d9ca
https://pure.amc.nl/en/publications/safety-pharmacodynamics-and-exposureresponse-modeling-results-from-a-firstinhuman-phase-1-study-of-nedosiran-phyox1-in-primary-hyperoxaluria(1c7005ba-03d0-46d6-9341-a3ec4ee99611).html
https://pure.amc.nl/en/publications/safety-pharmacodynamics-and-exposureresponse-modeling-results-from-a-firstinhuman-phase-1-study-of-nedosiran-phyox1-in-primary-hyperoxaluria(1c7005ba-03d0-46d6-9341-a3ec4ee99611).html
Autor:
Annelize Koch, Ulrike Lorch, Muna Albayaty, Joseph Cheriyan, Steffan Stringer, Shahzadgai Khan, Anthea Cromie, Michael Hammond, Jorg Taubel, Stuart Mair, Timothy C. Hardman, James Bush
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation and future challenges facing early phase drug development as we move into the second decade of the twenty first centu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a2415d807dd56827c179968d203e01
Publikováno v:
Regulatory Toxicology and Pharmacology. 92:226-238
The safety profile of Puritane™, a closed system electronic vapour product (EVP), was evaluated when used by smokers of conventional cigarettes (CCs) for 24 months in a real-life setting. The study was a two-centre ambulatory clinical study with 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3866c33d0c8e1efda41428b02fd47eee
https://doi.org/10.1016/j.yrtph.2017.12.010
https://doi.org/10.1016/j.yrtph.2017.12.010
Autor:
Mark Jones, Emma Jones, Annelize Koch, Payne Andrew Charles, Eugene Healy, Rodger A. Allen, Dominique Tytgat, Mark Watling, Eric Helmer
Publikováno v:
European Journal of Clinical Pharmacology
Purpose PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans. Methods These phase I, randomised,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56c9bf78178da4680cd3f4238c3c4f4
https://doi.org/10.1007/s00228-017-2205-7
https://doi.org/10.1007/s00228-017-2205-7